Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Autor: Equils O; Department of Pediatrics, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room 4220, Los Angeles, CA 90048, USA. ozlem.equils@cshs.org, Shapiro A, Madak Z, Liu C, Lu D

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2004 Oct; Vol. 48 (10), pp. 3905-11.

Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication.

Autor: Equils O; Division of Pediatric Infectious Diseases, Steven Spielberg Pediatric Research Center, Burns and Allen Research Institute, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles, CA 90048, USA. ozlem.equils@cshs.org, Schito ML, Karahashi H, Madak Z, Yarali A, Michelsen KS, Sher A, Arditi M

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2003 May 15; Vol. 170 (10), pp. 5159-64.